Skip to main content

Market Overview

Precision BioSciences: Q3 Earnings Insights



Shares of Precision BioSciences (NASDAQ:DTIL) remained unaffected after the company reported Q3 results.

Quarterly Results

Earnings per share were down 21.95% year over year to ($0.50), which beat the estimate of ($0.66).

Revenue of $7,363,000 up by 51.35% from the same period last year, which beat the estimate of $3,620,000.

Looking Ahead

Precision BioSciences hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.


Company's 52-week high was at $23.67

Company's 52-week low was at $4.46

Price action over last quarter: Up 18.02%

Company Description

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segments include Therapeutics and Food.


Related Articles (DTIL)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at